AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Buys 5,000 Shares
MarketBeat
AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein acquired 5,000 shares of the company's stock in a transaction that occurred on Tuesday, October 6th. The shares were acquired at an average cost of $8.70 per share, for a total transaction of $43,500.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company's stock, valued at $87,000. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.
NASDAQ:AGMB
